Enwei Pharmaceutical Co., Ltd.

301331

CNE100005LC7

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 18:00:00 2024-05-30 EDT			5-day change	1st Jan Change
26.81 ^CNY	+1.59%		+0.22%	-4.41%

05-14	Enwei Pharmaceutical Co., Ltd. Approves Cash Dividend for the Year 2023	CI
04-21	Enwei Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Tranche Update on Enwei Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on October 21, 2023.

January 02, 2024 at 11:00 am

From October 20, 2023 to December 31, 2023, the company has repurchased 708,541 shares, representing 1.01% for CNY 30.77 million. With this, the company has completed the repurchase of 708,541 shares, representing 1.01% for CNY 30.77 million under the buyback announced on October 21, 2023.

Latest news about Enwei Pharmaceutical Co., Ltd.

Enwei Pharmaceutical Co., Ltd. Approves Cash Dividend for the Year 2023	05-14	CI
Enwei Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	04-21	CI
Tranche Update on Enwei Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on October 21, 2023.	04-01	CI
Enwei Pharmaceutical Co., Ltd. Approves Appointment of Independent Directors and Non-Employee Supervisors	01-30	CI
Tranche Update on Enwei Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on October 21, 2023.	01-02	CI
Enwei Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-26	CI
Enwei Pharmaceutical Co., Ltd. announces an Equity Buyback for CNY 150 million worth of its shares.	23-10-20	CI
Enwei Pharmaceutical Co., Ltd. authorizes a Buyback Plan.	23-10-19	CI
Certain A Shares of Enwei Pharmaceutical Co., Ltd. are subject to a Lock-Up Agreement Ending on 20-SEP-2023.	23-09-19	CI
Enwei Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-27	CI
Enwei Pharmaceutical Co., Ltd. Announces Final Profit Distribution Plan to Be Implemented on A Shares for the Year 2022, Payable on 23 May 2023	23-05-16	CI
Enwei Pharmaceutical Co., Ltd. Approves Cash Dividend for the Year 2022	23-05-15	CI
Enwei Pharmaceutical Co., Ltd. Proposes Final Cash Dividend for 2022	23-04-24	CI
Enwei Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-21	CI
Enwei Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-26	CI
Enwei Pharmaceutical Co., Ltd. has completed an IPO in the amount of CNY 522.692 million.	22-09-08	CI

Chart Enwei Pharmaceutical Co., Ltd.

Duration

Period

More charts

Company Profile

Enwei Pharmaceutical Co Ltd is a China-based company mainly engaged in the research, development, production and sales of proprietary Chinese medicines and chemical medicines. The Company focuses on gynecological products, pediatric medicines, respiratory medicines and other fields. The Company's main products include Jieeryin lotion, Jieeryin ointment, Jieeryin effervescent tablets, Shanmai Jianpi oral liquid, Qingjing capsules and Danxiong Tongmai granules. Its products are mainly sold through direct sales and e-commerce. The Company principally conducts its businesses in the domestic market.

Sector

Pharmaceuticals

Calendar

2024-08-25 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ENWEI PHARMACEUTICAL CO., LTD.	-4.41%	370M
ELI LILLY AND COMPANY	+40.73%	739B
NOVO NORDISK A/S	+32.83%	598B
JOHNSON & JOHNSON	-6.30%	353B
MERCK & CO., INC.	+15.15%	318B
ABBVIE INC.	+4.05%	285B
ASTRAZENECA PLC	+15.00%	240B
ROCHE HOLDING AG	-5.52%	206B
AMGEN INC.	+6.17%	164B
PFIZER, INC.	-0.45%	162B